Neurovance Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Neurovance Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013493
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurovance Inc (Neurovance) is a clinical stage neuroscience focused company that develops centanafadine (CTN) SR for adult and pediatric Attention Deficit Hyperactivity Disorder (ADHD). CTN, formerly EB-1020, is a novel triple reuptake inhibitor that acts as a functional hybrid with activity intermediate between stimulants and non-stimulants; and increases dopamine activity. ADHD is the common childhood disorders that has three subtypes – hyperactive-impulsive; inattentive and combined hyperactive-impulsive and inattentive. The company received funds from various investors that include Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, and State of Wisconsin Investment Board (SWIB). Neurovance is headquartered in Cambridge, Massachusetts, the US.

Neurovance Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurovance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Neurovance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurovance Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Neurovance Acquires EB-1020 Program from Euthymics Bioscience 10
Venture Financing 11
Neurovance Raises USD0.6 Million in Venture Financing 11
Neurovance Raises Additional USD1.5 Million in Venture Financing 12
Neurovance Raises Additional USD5 Million Financing 13
Neurovance Raises USD1 Million in Financing Round 14
Neurovance Raises Additional USD5.5 Million in Venture Financing 15
Neurovance Raises Additional USD4 Million in Venture Financing 16
Neurovance Raises US$3.3 Million In Extended Series A1 Financing 17
Neurovance Raises USD3 Million in Venture Financing 18
Neurovance Raises US$6 Million In Series A1 Financing 19
Neurovance Raises Additional US$0.32 Million In Venture Financing 21
Acquisition 22
Otsuka Pharma to Acquire Neurovance 22
Neurovance Inc – Key Competitors 23
Neurovance Inc – Key Employees 24
Neurovance Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Dec 14, 2016: Neurovance Announces the Appointment of Brian Goff as Chief Operating Officer as the Company Prepares for the Next Stage of Growth and Development 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Neurovance Inc, Pharmaceuticals & Healthcare, Key Facts 2
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurovance Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurovance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurovance Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Neurovance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurovance Acquires EB-1020 Program from Euthymics Bioscience 10
Neurovance Raises USD0.6 Million in Venture Financing 11
Neurovance Raises Additional USD1.5 Million in Venture Financing 12
Neurovance Raises Additional USD5 Million Financing 13
Neurovance Raises USD1 Million in Financing Round 14
Neurovance Raises Additional USD5.5 Million in Venture Financing 15
Neurovance Raises Additional USD4 Million in Venture Financing 16
Neurovance Raises US$3.3 Million In Extended Series A1 Financing 17
Neurovance Raises USD3 Million in Venture Financing 18
Neurovance Raises US$6 Million In Series A1 Financing 19
Neurovance Raises Additional US$0.32 Million In Venture Financing 21
Otsuka Pharma to Acquire Neurovance 22
Neurovance Inc, Key Competitors 23
Neurovance Inc, Key Employees 24

★海外企業調査レポート[Neurovance Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rose Petroleum plc (ROSE):企業の財務・戦略的SWOT分析
    Summary Rose Petroleum Plc (Rose Petroleum), formerly Vane Minerals plc is an oil and gas company. The company explores and produce oil and gas, silver, gold, copper, and uranium deposits across the US and Mexico. Its oil and gas project is located in Paradox Basin in Utah, the US, which covers over …
  • Precision Optics Corporation Inc (PEYE):医療機器:M&Aディール及び事業提携情報
    Summary Precision Optics Corporation Inc (Precision Optics) is a medical device company that designs, develops, manufactures and distributes optics and optical systems for medical, biomedical, and industrial applications. The company provides custom optics solutions such as design and prototyping, f …
  • Emerald Resources NL (EMR):石油・ガス:M&Aディール及び事業提携情報
    Summary Emerald Resources NL (Emerald) is an oil and gas company that carries out mineral exploration and development. The company carries out acquisition, exploration, development and produces oil and natural gas, and gold deposits. Its projects include Okavu Gold project, and Magoffin County proje …
  • PolyNovo Ltd (PNV):企業の財務・戦略的SWOT分析
    Summary PolyNovo Ltd (PolyNovo), formerly Calzada Ltd, is a medical device company that develops, manufactures and commercializes biodegradable polymers for use in medical devices. The company provides products such as biodegradable temporizing matrix and negative pressure wound therapy dressing sys …
  • Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of …
  • Teledyne Technologies Incorporated:企業の戦略・SWOT・財務情報
    Teledyne Technologies Incorporated - Strategy, SWOT and Corporate Finance Report Summary Teledyne Technologies Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Lancer Systems L.P.:企業の戦略・SWOT・財務情報
    Lancer Systems L.P. - Strategy, SWOT and Corporate Finance Report Summary Lancer Systems L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • National Health Insurance Company – Daman PJSC:企業の戦略・SWOT・財務分析
    National Health Insurance Company – Daman PJSC - Strategy, SWOT and Corporate Finance Report Summary National Health Insurance Company – Daman PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • BC Hydro-エネルギー分野:企業M&A・提携分析
    Summary BC Hydro (BC) is a government-owned hydroelectric utility company that generates, distributes and supply power. It is a provincial Crown corporation owned by the Province of British Columbia. Through its subsidiary, Powerex, it buys and sells wholesale power, renewable energy, financial ener …
  • Egdon Resources Plc (EDR):企業の財務・戦略的SWOT分析
    Summary Egdon Resources Plc (Egdon) is oil and gas company that offers exploration and production services. The company explores and develops petroleum and natural gas assets in East Midlands, North East England, North West England, and Southern England, the UK. Its project site includes Wressle, No …
  • Phosphagenics Ltd:企業のM&A・事業提携・投資動向
    Phosphagenics Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Phosphagenics Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Cryo-Cell International Inc (CCEL):企業の財務・戦略的SWOT分析
    Summary Cryo-Cell International Inc (Cryo-Cell) operates as a cord blood bank service provider. The company offers biotechnology services, collection and preservation of umbilical cord blood stem cells for family use. It provides services such as cord blood banking, cord tissue banking, cord blood a …
  • Cosucra Groupe Warcoing SA:戦略・SWOT・企業財務分析
    Cosucra Groupe Warcoing SA - Strategy, SWOT and Corporate Finance Report Summary Cosucra Groupe Warcoing SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Calix Ltd (CXL):企業の財務・戦略的SWOT分析
    Calix Ltd (CXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • EpiVax Inc:企業の戦略的SWOT分析
    EpiVax Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • CohBar Inc (COB.U):企業の財務・戦略的SWOT分析
    Summary CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and C …
  • Micromem Technologies Inc (MRM):企業の財務・戦略的SWOT分析
    Summary Micromem Technologies Inc (Micromem) operates as a technology company that develops and markets magnetic sensor products. The company designs and develops sensors specific to industrial requirements. It offers solutions such as nanoparticle detection solutions, structural integrity sensors, …
  • Barclays Plc:企業のM&A・事業提携・投資動向
    Barclays Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Barclays Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Green Cross Cell Corp (031390)-製薬・医療分野:企業M&A・提携分析
    Summary Green Cross Cell Corp (Green Cross Cell), formerly Innocell Corp, a subsidiary of Green Cross Corp, is a provider of immunotherapeutics for the treatment of cancer. The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient. It offer …
  • Hybio Pharmaceutical Co Ltd (300199):製薬・医療:M&Aディール及び事業提携情報
    Summary Hybio Pharmaceutical Co Ltd (Hybio) is a peptide pharmaceutical company that develops and manufactures of polypeptide drugs. The company offers peptide finished dosage products and peptide active pharmaceutical ingredients. Its finished dosage products include desmopressin for injection, ter …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆